Trade Setup Breakdown for GOSS (30-Min Chart)!📊
🔹 Stock: GOSS (NASDAQ)
🔹 Timeframe: 30-Min Chart
🔹 Setup Type: Ascending Triangle Breakout
🚀 Trade Plan:
✅ Entry Zone: $1.22 - $1.25 (Breakout Confirmation)
✅ Stop-Loss (SL): $1.17 (Below Key Support)
🎯 Take Profit Targets:
📌 TP1: $1.34 (First Resistance)
📌 TP2: $1.44 (Extended Target)
📊 Risk-Reward Ratio Calculation:
📉 Risk (Stop-Loss Distance):
$1.24 - $1.17 = $0.07
📈 Reward to TP1:
$1.34 - $1.24 = $0.10
💰 Risk-Reward Ratio to TP1: 1:1.42
📈 Reward to TP2:
$1.44 - $1.24 = $0.20
💰 Risk-Reward Ratio to TP2: 1:2.85
🔍 Technical Analysis & Strategy:
📌 Breakout Confirmation: Price breaking the ascending triangle with momentum.
📌 Pattern Formation: Ascending Triangle Breakout, signaling bullish continuation.
📊 Key Support & Resistance Levels:
🟢 $1.17 (Support / SL Level)
🟢 $1.22 - $1.25 (Breakout Zone)
🟢 $1.34 (First Profit Target / Resistance)
🟢 $1.44 (Final Target for Momentum Extension)
🚀 Momentum Shift Expected:
If the price sustains above $1.25, we could see a rally towards $1.34 and beyond.
🔥 Trade Execution & Risk Management:
📊 Volume Confirmation: Ensure strong buying volume above $1.25 before entering.
📈 Trailing Stop Strategy: If the price reaches TP1 ($1.34), move SL to $1.25 to protect profits.
💰 Partial Profit Booking Strategy:
✔ Take 50% at $1.34, let the rest run to $1.44.
✔ Adjust Stop-Loss to Break-even ($1.25) after TP1 is hit.
⚠️ Fake Breakout Risk:
If price fails to hold above $1.22, be cautious and avoid entering early.
🚀 Final Thoughts:
✔ Bullish Setup – If price sustains above $1.25, a strong move is expected.
✔ Momentum Shift Possible – Watch for volume increase to confirm the trend.
✔ Favorable Risk-Reward Ratio – 1:1.42 to TP1, 1:2.85 to TP2.
💡 Stick to the plan, manage risk, and trade smart! 🚀🏆
GOSS trade ideas
GOSS - long - bottom & gap playGossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
This is not a financial advice!
A few block buys and passive stakes recently
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Keep an eye on 1.35, 1.55, 1.85, 3.0, 5.5, 6.8, levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 0.90
TP approx. midterm 3.0 if we fill the gap 8.0
Most info on the chart.
Trade carefully!
GOSS Penny Biotechology SHORTGOSS is a biotechnology penny stock without earnings valued based on future earnings
potential based on a "pipeline" which is subject to a long timeline of FDA regulation.
On the 30 minute chart. price is shown as being in the overvalued area in the upper VWAP
band and well above the POC line of the long-range volume profile. The RSI indicator is
now showing a bearish divergence as the relative strength is weakening. Price has bounced
down from the resistance of the line representing two standard deviations above VWAP.
The supply / demand zones are indicated by the Indicator applied which is authored by
Luxalgo. Price has hit the supply zone lower border and is now in an early reversal.
I see this as a swing short trade also played with taking put options. Stop loss is
in the upper area of the red supply zone. Targets include first the POC line of the volume
profile and then a final target at one STD below VWAP also being just above the demand zone.
Alternatively put options at the strike of $ 1.50 for the May monthly expiration of 5/18
This trade will benefit from any expected pullback in the general markets.
GOSS - short squeeze - phase 2 catalystThis is not a financial advice!
Upcoming catalyst and block buys recently.
SL under 0.97
Key level: 1.4 must be broken and hold for bullish confirmation.
TP 1 around 3.0
TP 2 around 6.0
TP 3 around 9.0
Only 89.93M float
18.97% Short float
Most info on the chart.
Trade carefully!
Biotechs are on fire! Gossamer and upcoming event! Biotechnology is the favorite sector of one of our analysts, most of his portfolio consists of biotechs, and he himself claims that it is the cryptocurrency of the common stock market.
Why? Let's explain :
High risk/reward and high volatility.
Imagine this: you invest in a company that has no revenue or any specific product, yet you believe in the idea it promotes. You're taking giant risks because it's far from clear what to expect.
But for that you get a great opportunity to make a quick buck. In biotech, soaring by 20%, 30%, or even 100% is the absolute norm. But you have to approach it carefully, because if you fail, the reaction can be devastating.
Here is an example of successful investment in biotech companies:
Axsome Therapeutics
Ranks: 48.
The company recently grew by more than 30% after successful results from a clinical trial of its drug to treat agitation in Alzheimer's disease.
Cool? Absolutely.
Our analysts have found another attractive company with a catalyst in the coming days!
Its name is Gossamer Bio.
Ranks: 11
Financials are really weak, the Ranks system also gives it a low rating, but the coming catalyst could immediately change everything. In the coming days, the company is expected to present the data of phase 2 of its core drug GB002. Take a closer look at the company!
Biotechs are scam or great potential
GOSS Rally ?This stock jumped to the top of my proprietary algorithm about 2 weeks ago; set the alert and it fired a few days ago.
The chart shown is as simple as it gets; see expected price action on chart and be sure to review the comments box.
Set your alerts, stop loss, etc. as needed.
Feedback always welcome.
Gossamer Bio longGossamer Bio
Healthcare
Biotechnology
USA
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States and is headquartered in San Diego, California.
- High volume in stock
- Crossed 200 EMA
- Next earnings date - 10 Aug 2022
GOSS - Trend reversal quietly going on? Over the last month, GOSS has managed to break out of the big RED falling channel, and in the last sessions, it looks like it may also be breaking out of the big BLACK symmetrical triangle. This morning it has traded as high as 9% above yesterday's close, and while the day is still long, these are exciting signs of life indeed. If it can gather some momentum, it could test the 200 dma for a quick 11% gain from current price; above that resistance, there are a couple YELLOW trendlines at +17% and +47%. I believe that in the long term it will go back to all-time highs for a +100% gain from today, but both this stock AND the sector it belongs to (post-IPO biotech stocks) are so volatile and unpredictable that I'm not making any kind of time forecast on when those targets could be reached. It could be a great buy-and-hold for the next couple years.
Full disclosure: long GOSS at 1% of total assets. Very aggressive play, as are all post-IPO biotech stocks. Do NOT tie up too much capital in any of this ideas, there's NO telling when gains may finally start rolling in!!!
GOSSAMER BIO on verge of bullish break. ----ENTRY LEVEL $21.40 ------TARGET PRICE $23-----
COMPANY PROFILE
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate is GB001, which is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.